ARTICLE
2 August 2021

Supreme Court Of Canada Denies Amgen Leave To Appeal Decision Invalidating Its Filgrastim Patent

SB
Smart & Biggar
Contributor
Smart & Biggar is Canada's largest firm practicing exclusively in intellectual property and technology law, with offices in Ottawa, Toronto, Montréal, Vancouver and Calgary. We are leaders in intellectual property and have been serving clients for over a century. Intellectual property rights are only valuable if they can be protected and exploited intelligently. At Smart & Biggar we are devoted to maximizing the value of our clients' intellectual property and technology assets. While we are proud that we have been selected repeatedly as Canada's leading intellectual property firm in numerous Canadian and international surveys, we recognize that our success is best measured by your success. Smart & Biggar operates as part of the IPH Limited group, under its own brand and independent from other IPH member firms. For more information, please visit https://www.smartbiggar.ca/
As previously reported, Amgen sought leave to appeal a decision of the Federal Court of Appeal (2020 FCA 188) affirming Justice Southcott's decision that the relevant claims of its filgrastim (NEUPOGEN)
Canada Intellectual Property
To print this article, all you need is to be registered or login on Mondaq.com.

As previously reported, Amgen sought leave to appeal a decision of the Federal Court of Appeal (2020 FCA 188) affirming Justice Southcott's decision that the relevant claims of its filgrastim (NEUPOGEN) patent were invalid for obviousness. On July 9, 2021, the Supreme Court of Canada denied leave to Amgen (Docket No. 39530).

Amgen has discontinued its pending patent infringement actions under the PMNOC Regulations against biosimilar manufacturers Mylan (FULPHILA), Purdue Pharma (PELMEG), and Sandoz (ZIEXTENZO).

Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

ARTICLE
2 August 2021

Supreme Court Of Canada Denies Amgen Leave To Appeal Decision Invalidating Its Filgrastim Patent

Canada Intellectual Property
Contributor
Smart & Biggar is Canada's largest firm practicing exclusively in intellectual property and technology law, with offices in Ottawa, Toronto, Montréal, Vancouver and Calgary. We are leaders in intellectual property and have been serving clients for over a century. Intellectual property rights are only valuable if they can be protected and exploited intelligently. At Smart & Biggar we are devoted to maximizing the value of our clients' intellectual property and technology assets. While we are proud that we have been selected repeatedly as Canada's leading intellectual property firm in numerous Canadian and international surveys, we recognize that our success is best measured by your success. Smart & Biggar operates as part of the IPH Limited group, under its own brand and independent from other IPH member firms. For more information, please visit https://www.smartbiggar.ca/
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More